Page Title
Clinical Trial Finder
Blaze a trail to better treatments and a cure for cystic fibrosis.
As a clinical trial volunteer, you are paving the way for new treatments. Search or filter for trials that may be right for you, or learn more about what it means to be a trailblazer.
Showing 1-5 of 5 studies
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn more about what it means to be a trailblazer.
Showing 1-5 of 5 studies
-
Restore CFTR FunctionCompleted with Results
Study of VX-445 Triple Combination in Teens and Adults With Cystic Fibrosis (CF) Who Have One Copy of F508del and One Copy of a Gating or Residual Function Mutation , protocol number Vertex VX18-445-104This study evaluated the safety and effectiveness of VX-445 (elexacaftor), tezacaftor, and ivacaftor in combination called TRIKAFTA®. This study was for people with CF 12 years and older with one copy of the F508del mutation and one copy of a gating or residual function mutation.
-
Age:
12 Years and Older
-
Mutation(s):
One Copy F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
8
-
Length of Participation:
20 weeks
-
-
Restore CFTR FunctionCompleted with Results
Study of VX-445 triple combination in children 6-11 years old with cystic fibrosis , protocol number Vertex VX18-445-106This study evaluated the safety and effectiveness of the triple combination modulator therapy, elexacaftor/tezacaftor/ivacaftor (Trikafta®) in children ages 6-11 years with CF, who have either two copies of the F508del mutation or one copy of the F508del mutation and one minimal function mutation.
-
Age:
6 Years to 11 Years
-
Mutation(s):
Two Copies F508del or One Copy F508del
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
9
-
Length of Participation:
32 weeks
-
-
Restore CFTR FunctionCompleted with Results
Study of VX-445 plus ivacaftor and tezacaftor in people with CF who have two copies of the F508del CFTR mutation , protocol number Vertex VX17-445-103This study evaluated the effectiveness and safety of the CFTR modulator drug VX-445 (elexacaftor) in combination with ivacaftor and tezacaftor. This triple combination is known as Trikafta™. This study was for people with CF ages 12 and older who have two copies of the F508del CFTR mutation and were already taking tezacaftor plus ivacaftor.
-
Age:
12 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
7
-
Length of Participation:
10 weeks
-
-
Restore CFTR FunctionCompleted with Results
Study of effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in people with CF who have one copy of the F508del CFTR mutation , protocol number Vertex VX17-445-102This study evaluated the effectiveness and safety of the CFTR modulator drug VX-445 (elexacaftor) in combination with tezacaftor and ivacaftor (ELX/TEZ/IVA). This triple combination drug is known as Trikafta™. This study was for people with cystic fibrosis ages 12 and older with one copy of the F508del CFTR mutation and one copy of a minimal function mutation.
-
Age:
12 Years and Older
-
Mutation(s):
One Copy F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
10
-
Length of Participation:
32 weeks
-
-
Restore CFTR FunctionCompleted with Results
Phase 1/2 study of VX-445 combination drug in healthy adults and then in people with cystic fibrosis , protocol number VX-445-001This study evaluated the safety, tolerability and effectiveness of the drug VX-445 in combination with tezacaftor/ivacaftor (Symdeko®) in people who either have two copies of the F508del CFTR mutation or have one copy of F508del and one copy of a minimal function CFTR mutation.
-
Age:
18 Years and Older
-
Mutation(s):
Two Copies F508del or One Copy F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
6
-
Length of Participation:
12 weeks
-
Showing 1-5 of 5 studies
- 1
Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More